

Date: 10 November 2025

To

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip Code: 544293

The Secretary
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1 G Block
Bandra -Kurla Complex, Bandra (East)
Mumbai- 400 051
Scrip Symbol: SURAKSHA

Dear Sir / Ma'am,

Sub: Outcome of the Board meeting held today i.e. Monday, 10 November 2025

Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time

With further reference to our letter dated 03 November 2025, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. on Monday, 10 November 2025, has *inter alia*, considered and approved the unaudited (standalone and consolidated) financial results of the Company for the quarter and six months ended 30 September 2025 along with Limited Review Report thereon, issued by the Statutory Auditors of the Company, enclosed herewith as **Annexure-1**.

The meeting of the Board of Directors commenced at **2.30 pm** (IST) and concluded at **4.15 pm** (IST).

You are requested to kindly take the same on record.

For Suraksha Diagnostic Limited

Mamta Jain
Company Secretary & Compliance Officer

Encl: As above

Independent Auditor's Review Report on unaudited standalone financial results of Suraksha Diagnostic Limited for the quarter and year to date ended September 30, 2025 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of Suraksha Diagnostic Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Suraksha Diagnostic Limited (hereinafter referred to as 'the Company') for the quarter ended September 30, 2025 and the year-to-date results for the period from April 01, 2025 to September 30, 2025 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MSKA & Associates**
Chartered Accountants
ICAI Firm Registration No.105047W



Dipak Jaiswal
Membership No.: 063682

UDIN: 25063682BM0T995557



Place: Kolkata
Date: November 10, 2025

Suraksha

Clinic & Diagnostics

Suraksha Diagnostic Limited
Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India
(CIN : L85110WB2005PLC102265)
Website : www.surakshanet.com

Statement of unaudited standalone financial results for the quarter and half year ended 30 September 2025

(₹ in lakhs)

Particulars	Quarter ended			Six month ended		Year ended
	30 September 2025 (Unaudited)	30 June 2025 (Unaudited)	30 September 2024 (Unaudited)	30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	31 March 2025 (Audited)
Income						
I Revenue from operations	7,626.33	7,027.90	6,594.74	14,654.23	12,638.03	24,909.54
II Other income	96.72	109.57	125.55	206.29	246.64	438.30
III Total Income	7,723.05	7,137.47	6,720.29	14,860.52	12,884.67	25,347.84
IV Expenses						
Cost of materials consumed	880.38	868.80	782.71	1,749.18	1,436.83	2,894.54
Employee benefits expenses	1,298.98	1,241.48	1,071.10	2,540.46	2,089.64	4,190.58
Finance costs	271.76	265.85	207.39	537.61	428.91	838.53
Depreciation and amortisation expense	965.34	915.37	857.66	1,880.71	1,745.35	3,472.83
Impairment loss/(gain)	20.45	(89.04)	34.33	(68.59)	50.15	218.58
Other expenses	3,029.19	2,622.93	2,349.28	5,652.12	4,593.78	9,346.81
Total expenses (IV)	6,466.10	5,825.39	5,302.47	12,291.49	10,344.66	20,961.87
V Profit before tax and exceptional items (III-IV)	1,256.95	1,312.08	1,417.82	2,569.03	2,540.01	4,385.97
VI Exceptional items	-	-	-	-	-	-
VII Profit before tax (V-VI)	1,256.95	1,312.08	1,417.82	2,569.03	2,540.01	4,385.97
VIII Income tax expense						
(i) Current tax expense	308.49	285.67	357.73	594.16	666.89	1,066.83
(ii) Tax pertaining to earlier period/years	-	-	-	-	-	(38.22)
(iii) Deferred tax expense/(credit)	12.09	41.54	(14.50)	53.63	(34.52)	13.36
Total tax expense (VIII)	320.58	327.21	343.23	647.79	632.37	1,041.97
IX Profit for the period/year (VII-VIII)	936.37	984.87	1,074.59	1,921.24	1,907.64	3,344.00
X Other comprehensive income						
(a) Items that will not be reclassified subsequently to profit or loss						
(i) Remeasurement gain/(loss) of net defined benefit plan	(0.56)	26.00	4.60	25.44	(35.13)	(27.25)
(ii) Income tax effect on above	0.14	(6.54)	(1.16)	(6.40)	8.84	6.86
Other comprehensive income/(losses) for the period/year, net of tax	(0.42)	19.46	3.44	19.04	(26.29)	(20.39)
XI Total comprehensive income for the period/year	935.95	1,004.33	1,078.03	1,940.28	1,881.35	3,323.61
XII Paid-up equity share capital (face value - Rs. 2 per share)	1,041.62	1,041.62	862.50	1,041.62	862.50	1,041.62
XIII Other equity	-	-	-	-	-	20,389.60
XIV Earnings per equity share (Face Value of Rs 2 each)						
- Basic (Rs) (not annualised except for year end figures)	1.80	1.89	2.02	3.69	3.58	6.42
- Diluted (Rs) (not annualised except for year end figures)	1.80	1.89	2.02	3.69	3.58	6.42



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

Suraksha

Clinic & Diagnostics

Suraksha Diagnostic Limited

Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India

(CIN : L85110WB2005PLC102265)

Website : www.surakshanet.com

Unaudited Standalone Statement of Assets and Liabilities as at 30 September 2025

(₹ in lakhs)

Particulars	As at 30 September 2025 (Unaudited)	As at 31 March 2025 (Audited)
Assets		
Non-current assets		
a) Property, plant and equipment	15,363.81	13,938.29
b) Capital work-in-progress	188.10	532.03
c) Right-of-use assets	10,192.03	7,429.02
d) Intangible assets	133.12	148.00
e) Intangible assets under development	90.53	49.34
f) Financial assets		
i) Investments	631.11	271.48
ii) Loans	1,567.87	1,387.23
iii) Other financial assets	1,494.88	4,263.66
g) Non-current tax assets (net)	422.44	161.31
h) Other non-current assets	764.43	702.61
Total non-current assets (A)	30,848.32	28,882.97
Current assets		
a) Inventories	841.88	801.65
b) Financial assets		
i) Trade receivables	1,556.38	1,505.80
ii) Cash and cash equivalents	123.60	147.54
iii) Bank balances other than cash and cash equivalents	3,758.24	1,405.31
iv) Other financial assets	100.98	252.17
c) Other current assets	532.31	314.59
Total current assets (B)	6,913.39	4,427.06
Total Assets (A+B)	37,761.71	33,310.03
Equity and Liabilities		
Equity		
a) Equity share capital	1,041.62	1,041.62
b) Other equity	22,387.62	20,389.60
Total equity (A)	23,429.24	21,431.22
Liabilities		
Non-current liabilities		
a) Financial liabilities		
i) Borrowings	69.60	287.54
ii) Lease liabilities	9,923.46	7,122.81
b) Provisions	93.89	102.22
c) Deferred tax liabilities (net)	605.12	545.09
Total non-current liabilities (B)	10,692.07	8,057.66
Current liabilities		
a) Financial liabilities		
i) Borrowings	191.59	294.98
ii) Lease liabilities	1,338.73	1,183.76
iii) Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	124.60	196.74
- Total outstanding dues other than above micro enterprises and small enterprises	1,411.97	1,202.11
iv) Other financial liabilities	314.08	713.25
b) Other current liabilities	246.16	217.79
c) Provisions	13.27	12.52
Total current liabilities (C)	3,640.40	3,821.15
Total liabilities (B+C)	14,332.47	11,878.81
Total equity and liabilities (A+B+C)	37,761.71	33,310.03



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

Suraksha

Clinic & Diagnostics

Suraksha Diagnostic Limited

Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India

(CIN : L85110WB2005PLC102265)

Website : www.surakshanet.com

Unaudited Standalone Statement of Cash Flow for the half year ended 30 September 2025

(₹ in lakhs)

Particulars	Period ended 30 September 2025	Period ended 30 September 2024
Cash flow from operating activities		
Profit before tax	2,569.02	2,540.01
Adjustments for:		
Depreciation and amortisation expense	1,880.71	1,745.35
Finance costs	537.61	428.91
Interest on loans, deposits and IT refund	(187.82)	(206.10)
Unwinding of security deposit	(17.08)	(16.57)
Loss on sale of property, plant and equipment	29.25	25.41
Impairment Loss/(gain)	(68.59)	50.15
Security deposits written off	-	6.65
Bad debts written off	-	26.78
Share based payment expenses	57.75	-
Liabilities/ provisions no longer required written back	-	(22.96)
Operating profit before working capital changes	4,800.85	4,577.63
Changes in operating assets and liabilities		
Adjustments for (increase) / decrease in operating assets		
Trade receivables	29.50	(145.18)
Inventories	(40.23)	(18.96)
Other financial assets	168.22	(943.82)
Other current assets	(217.70)	(179.44)
Adjustments for increase / (decrease) in operating liabilities		
Trade payables	137.72	54.99
Other current liabilities	28.37	8.30
Other financial liabilities	(300.50)	(3.08)
Provisions	17.86	52.15
Cash generated from operations	4,624.09	3,402.59
Income tax paid (net)	(855.30)	(428.15)
Net cash flows generated from operating activities (A)	3,768.79	2,974.44
Cash flows from investing activities		
Purchase of property, plant & equipment, other intangible assets and Intangible Asset under Development (including capital work-in-progress, capital advances and capital	(2,325.48)	(1,003.78)
Proceeds from sale of property, plant & equipment	9.17	14.99
Net Redemption/(Investment) in deposits with banks	330.11	(169.82)
Investment in Subsidiaries	(359.63)	(55.00)
Loan given to Subsidiaries	(130.69)	(730.85)
Interest received on bank deposits	154.95	162.67
Net cash flows used in investing activities (B)	(2,321.57)	(1,781.79)
Cash flow from financing activities		
Repayment of borrowings	(321.33)	(179.95)
Payment of lease liabilities	(1,130.07)	(1,039.67)
Finance cost paid	(19.76)	(41.31)
Net cash flows used in financing activities (C)	(1,471.16)	(1,260.93)
Net increase in cash and cash equivalents (A+B+C)	(23.94)	(68.28)
Cash and cash equivalents at the beginning of the period	147.54	210.94
Cash and cash equivalents at the end of the period	123.60	142.66



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com


Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

Notes to the unaudited standalone financial results

1. The unaudited standalone financial results for the quarter and six months ended 30 September 2025 ("the financial results") of Suraksha Diagnostic Limited ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations").
2. These unaudited standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 10 November 2025. The statutory auditor have carried out limited review on these financial results and have issued an unmodified conclusion.
3. The Company is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 – 'Operating Segments'.
4. The Company has completed the acquisition of Fetomat Wellness Private Limited ('Fetomat') on April 08, 2025 by acquisition of 3,73,423 equity shares of equity shares of ₹10/- each representing 63% of the total equity share capital of Fetomat, resulting in Fetomat becoming a subsidiary of the Company.
5. These unaudited standalone financial results are also available on the Company's website (www.surakshanet.com) and on the stock exchange websites (www.bseindia.com and www.nseindia.com).
6. Previous period's/year's figures have been regrouped/reclassified wherever necessary to conform to current period's/ year's classification.



For and on behalf of Board of Directors of
Suraksha Diagnostic Limited


Dr. Somnath Chatterjee
Chairman & Joint Managing Director
DIN: 00137075

Place: Kolkata
Date: 10 November 2025

Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

Independent Auditor's Review Report on unaudited consolidated financial results of Suraksha Diagnostic Limited for the quarter and year to date ended September 30, 2025 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Suraksha Diagnostic Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Suraksha Diagnostic Limited (hereinafter referred to as 'the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended September 30, 2025 and the year-to-date results for the period from April 01, 2025 to September 30, 2025 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Suraksha Speciality LLP	Subsidiary
2	Asian Institute of Immunology & Rheumatology LLP (AIIR)	Subsidiary
3	Suraksha Radiology Private Limited	Subsidiary
4	Suraksha Advanced Radiology Private Limited	Subsidiary
5	Fetomat Wellness Private Limited	Subsidiary
6	Suraksha Salvia LLP	Step-down subsidiary



MSKA & Associates

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of six subsidiaries included in the Statement, whose interim financial statements reflects total assets of Rs. 2581.45 lakhs as at September 30, 2025 and total revenues of Rs. 319.75 lakhs and Rs. 610.15 lakhs, total net loss after tax of Rs. 53.56 lakhs and Rs. 120.80 lakhs and total comprehensive income of Rs. (53.56) lakhs and Rs. (120.80) lakhs for the quarter ended 30 September 2025 and for the period from April 01, 2025 to September 30, 2025 respectively, and cash flows (net) of Rs. (22.55) lakhs for the period from 01 April 2025 to 30 September 2025, as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and reports of the other auditors.

For **M S K A & Associates**
Chartered Accountants
ICAI Firm Registration No.105047W



Dipak Jaiswal
Membership No.: 063682

UDIN: 25063682BMOTQR6938



Place: Kolkata
Date: November 10, 2025

Statement of unaudited consolidated financial result for the quarter and half year ended 30 September 2025

(₹ in lakhs)

Particulars	Quarter ended			Six month ended		Year ended
	30 September 2025 (Unaudited)	30 June 2025 (Unaudited)	30 September 2024 (Unaudited)	30 September 2025 (Unaudited)	30 September 2024 (Unaudited)	31 March 2025 (Audited)
Income						
I Revenue from operations	7,872.90	7,258.63	6,675.35	15,131.53	12,748.50	25,209.27
II Other income	85.14	90.57	131.32	175.71	243.01	384.60
III Total Income	7,958.04	7,349.20	6,806.67	15,307.24	12,991.51	25,593.87
IV Expenses						
Cost of materials consumed	890.08	875.05	793.12	1,765.13	1,456.79	2,951.91
Employee benefits expenses	1,339.16	1,277.47	1,102.12	2,616.63	2,140.03	4,289.03
Finance costs	277.58	270.49	212.53	548.07	434.05	838.53
Depreciation and amortisation expense	1,014.32	948.24	874.89	1,962.56	1,774.17	3,529.77
Impairment loss/(gain)	20.45	(89.04)	34.33	(68.59)	50.15	218.58
Other expenses	3,211.76	2,820.12	2,426.39	6,031.88	4,721.71	9,625.52
Total expenses (IV)	6,753.35	6,102.33	5,443.38	12,855.68	10,576.90	21,453.34
V Profit before tax and exceptional items (III-IV)	1,204.69	1,246.87	1,363.29	2,451.56	2,414.61	4,140.53
VI Exceptional items						
VII Profit before tax (V-VI)	1,204.69	1,246.87	1,363.29	2,451.56	2,414.61	4,140.53
VIII Income tax expense						
(i) Current tax expense	309.83	287.82	357.73	597.65	666.89	1,067.60
(ii) Tax pertaining to earlier years						(38.22)
(iii) Deferred tax expense/(credit)	12.09	41.54	(10.00)	53.63	(34.52)	13.36
Total tax expense (VIII)	321.92	329.36	347.73	651.28	632.37	1,042.74
IX Profit for the period/year (VII-VIII)	882.77	917.51	1,015.56	1,800.28	1,782.24	3,097.79
X Other comprehensive income						
(a) Items that will not be reclassified subsequently to profit or loss						
(i) Remeasurement gain/(loss) of net defined benefit plan	(0.56)	26.00	4.60	25.44	(35.13)	(27.25)
(ii) Income tax effect on above	0.14	(6.54)	(1.16)	(6.40)	8.84	6.86
Other comprehensive income/(losses) for the period/year, net of tax	(0.42)	19.46	3.44	19.04	(26.29)	(20.39)
XI Total comprehensive income for the period/year	882.35	936.97	1,019.00	1,819.32	1,755.95	3,077.40
XII Profit for the period/year attributed to						
Owners of the parent	898.64	939.74	1,034.29	1,838.38	1,828.18	3,182.41
Non- controlling interests	(15.87)	(22.23)	(18.73)	(38.10)	(45.94)	(84.62)
	882.77	917.51	1,015.56	1,800.28	1,782.24	3,097.79
XIII Other comprehensive income for the period/year attributable to						
Owners of the parent	(0.42)	19.46	3.44	19.04	(26.29)	(20.39)
Non- controlling interests	(0.42)	19.46	3.44	19.04	(26.29)	(20.39)
XIV Total comprehensive income for the period/year attributable to						
Owners of the parent	898.22	959.20	1,037.73	1,857.42	1,801.89	3,162.02
Non- controlling interests	(15.87)	(22.23)	(18.73)	(38.10)	(45.94)	(84.62)
	882.35	936.97	1,019.00	1,819.32	1,755.95	3,077.40
XV Paid-up equity share capital (face value - Rs. 2 per share)	1041.62	1,041.62	862.50	1,041.62	862.50	1,041.62
XVI Other equity (including Non-controlling interest)						20,082.35
XVII Earnings per equity share (Face Value of 2 each (Rs))						
- Basic (Rs) (not annualised except for year end figures)	1.73	1.80	1.94	3.53	3.43	5.97
- Diluted (Rs) (not annualised except for year end figures)	1.73	1.80	1.94	3.53	3.43	5.97



Suraksha

Clinic & Diagnostics

Suraksha Diagnostic Limited
Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India
(CIN : L85110WB2005PLC102265)
Website : www.surakshanet.com

Unaudited Consolidated Statement of Assets and Liabilities as at 30 September 2025

(₹ in lakhs)

Particulars	As at 30 September 2025 (Unaudited)	As at 31 March 2025 (Audited)
Assets		
Non-current assets		
a) Property, plant and equipment	16,698.11	14,713.71
b) Capital work-in-progress	188.10	1,009.93
c) Right-of-use assets	10,420.91	7,429.02
d) Goodwill	388.01	-
e) Intangible assets	135.13	150.00
f) Intangible Assets under Development	90.53	49.34
g) Financial assets		
i) Investments		100.00
ii) Other financial assets	1,505.07	4,269.13
h) Non-current tax assets (net)	440.77	162.75
i) Other non-current assets	815.97	753.27
Total non-current assets (A)	30,682.60	28,637.14
Current assets		
a) Inventories	844.61	804.89
b) Financial assets		
i) Trade receivables	1,362.76	1,381.23
ii) Cash and cash equivalents	210.72	224.68
iii) Bank balances other than cash and cash equivalents	4,148.70	1,785.89
iv) Other financial assets	100.98	253.02
c) Other current assets	674.42	265.57
Total current assets (B)	7,342.19	4,715.28
Total Assets (A+B)	38,024.79	33,352.42
Equity and Liabilities		
Equity		
a) Equity share capital	1,041.62	1,041.62
b) Other equity	21,997.52	20,082.35
c) Equity attributable to owners of the parent (a+b)	23,039.14	21,123.97
d) Non Controlling interest	(96.90)	(100.86)
Total equity (A)	22,942.24	21,023.11
Liabilities		
Non-current liabilities		
a) Financial liabilities		
i) Borrowings	76.26	287.54
ii) Lease liabilities	10,131.24	7,122.79
b) Provisions	93.89	102.22
c) Deferred tax liabilities (net)	603.29	545.09
Total non-current liabilities (B)	10,904.68	8,057.65
Current liabilities		
a) Financial liabilities		
i) Borrowings	193.46	294.98
ii) Lease liabilities	1,368.47	1,183.76
iii) Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	124.60	196.74
- Total outstanding dues other than above micro enterprises and small enterprises	1,514.10	1,167.61
iv) Other financial liabilities	675.93	1,077.23
b) Other current liabilities	282.72	338.04
c) Provisions	13.27	12.52
d) Current tax liabilities (net)	5.32	0.77
Total current liabilities (C)	4,177.87	4,271.66
Total liabilities (B+C)	15,082.55	12,329.31
Total equity and liabilities (A+B+C)	38,024.79	33,352.42



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265



Suraksha Clinic & Diagnostics

Suraksha Diagnostic Limited
Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India
(CIN : L85110WB2005PLC102265)
Website : www.surakshanet.com

Unaudited Consolidated Statement of Cash Flows for the half year ended 30 September 2025

Particulars	Period ended 30 September 2025	Period ended 30 September 2024
Cash flow from operating activities		
Profit before tax	2,451.56	2,414.61
Adjustments for:		
Depreciation and amortisation expenses		
Finance costs	1,962.57	1,774.17
Interest on loans, deposits and IT refund	548.07	434.05
Unwinding of security deposit	(146.12)	(182.54)
Loss on sale of property, plant and equipment	(17.20)	(16.57)
Impairment Loss/(gain)	29.25	25.58
Security deposits written off	(68.59)	50.15
Bad debts written off	-	6.65
Share based payment expenses	-	26.78
Liabilities/ provisions no longer required written back	57.75	-
	(0.31)	(22.96)
Operating profit before working capital changes	4,816.98	4,509.92
Changes in operating assets and liabilities		
Adjustments for (increase) / decrease in operating assets		
Trade receivables	100.19	(73.39)
Inventories	(38.57)	(17.57)
Other financial assets	168.64	(946.16)
Other assets	(408.85)	(211.42)
Adjustments for increase / (decrease) in operating liabilities		
Trade payables	257.70	(41.80)
Other liabilities	(70.31)	880.24
Other financial liabilities	(302.63)	4.67
Provisions	17.86	52.15
Cash generated from operations	4,541.01	4,156.64
Income tax paid (net)	(871.70)	(428.21)
Net cash flows generated from operating activities (A)	3,669.31	3,728.43
Cash flows from investing activities		
Purchase of property, plant & equipment, other intangible assets and intangible asset under development (including capital work-in-progress, capital advances and capital creditors)	(2,346.15)	(1,990.93)
Proceeds from sale of property, plant & equipment	9.17	14.99
Net Redemption/(Investments) in deposits with banks	320.23	(726.29)
Acquisition of Subsidiary, net of cash acquired	(327.10)	-
Interest received on bank deposits	163.32	180.54
Net cash flows used in investing activities (B)	(2,180.53)	(2,521.69)
Cash flow from financing activities		
Contribution from non-controlling interests	-	10.00
Repayment of borrowings	(332.76)	(179.95)
Payment of lease liabilities	(1,149.35)	(1,039.67)
Finance cost paid	(20.63)	(46.45)
Net cash flows used in financing activities (C)	(1,502.74)	(1,256.07)
Net increase in cash and cash equivalents (A+B+C)	(13.96)	(49.33)
Cash and cash equivalents at the beginning of the year	224.68	252.00
Cash and cash equivalents at the end of the year	210.72	202.67



Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265

Notes to the unaudited consolidated financial results

1. The unaudited consolidated financial results for the quarter and six months ended 30 September 2025 ("the financial results") of Suraksha Diagnostic Limited ("the Holding Company") and its subsidiary (Holding company and subsidiaries together referred to as 'the group') have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the regulations").
2. These unaudited consolidated financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 10 November 2025. The statutory auditor have carried out limited review on these financial results and have issued an unmodified conclusion.
3. The Group is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 –'Operating Segments'.
4. The Holding Company has completed the acquisition of Fetomat Wellness Private Limited ('Fetomat') on April 08, 2025 by acquisition of 3,73,423 equity shares of equity shares of ₹10/- each representing 63% of the total equity share capital of Fetomat, resulting in Fetomat becoming a subsidiary of the Company. As per Ind AS 103 Business Combinations, the transaction has been accounted for and the difference between the consideration paid on acquisition and the fair value of net identifiable assets acquired attributed to the Holding Company has been accounted for as Goodwill as on the date of acquisition.
5. These unaudited consolidated financial results are also available on the Holding Company's website (www.surakshanet.com) and on the stock exchange websites (www.bseindia.com and www.nseindia.com).
6. Previous period's/year's figures have been regrouped/reclassified wherever necessary to conform to current period's/ year's classification.



For and on behalf of Board of Directors of
Suraksha Diagnostic Limited

Dr. Somnath Chatterjee
Chairman & Joint Managing Director
DIN: 00137075

Place: Kolkata
Date: 10 November 2025

Suraksha Diagnostic Limited

Head Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata - 700156.

E-mail: info@surakshanet.com | Website: www.surakshanet.com

Phone: (033) 66059750 | CIN : L85110WB2005PLC102265